Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA‐seq of comprehensively examine variations in MHCC-97H cells treated with various doses of lenvatinib at the transcriptomic level.

ABSTRACT: RNA‐seq of comprehensively examine variations in MHCC-97H cells treated with various doses of lenvatinib at the transcriptomic level.

PROVIDER: PRJNA884761 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21730941_1.fastq.gz	Fastqsanger.gz
	SRR21730941_2.fastq.gz	Fastqsanger.gz
	SRR21730942_1.fastq.gz	Fastqsanger.gz
	SRR21730942_2.fastq.gz	Fastqsanger.gz
	SRR21730943_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

RNA‐seq of comprehensively examine variations in MHCC-97H cells treated with various doses of lenvatinib at the transcriptomic level.

Project description:To determine the drug target of lenvatinib, RNAseq was used to evaluate the transcriptome differences between lenvatinib-treated MHCC-97H cells and their parental counterparts.Results show that SERPINE1 may be direct target of lenvatinib, and AKR1C1 have potential prognostic significance in the prediction of LR(lenvatinib-resistant) in HCC. AKR1C1 could be a promising therapeutic target for patients with LR-type liver cancer.

2022-11-01 | GSE214324 | GEO

Human hepatocellular carcinoma MHCC-97H: Control vs ROCK1 overexpressed vs ROCK2 overexpressed

Project description:Transcriptional profiling of human hepatoellular carcinoma (HCC) cell line: MHCC-97H comparing control untreated MHCC-97H cells with MHCC-97H cells overexpressed ROCK1 protein. Goal was to determine the effect of ROCK1 on global MHCC-97H cell mRNA and lncRNA expression. Transcriptional profiling of human hepatoellular carcinoma (HCC) cell line: MHCC-97H comparing control untreated MHCC-97H cells with MHCC-97H cells overexpressed ROCK2 protein. Goal was to determine the effect of ROCK2 on global MHCC-97H cell mRNA and lncRNA expression. Transcriptional profiling of human hepatoellular carcinoma (HCC) cell line: MHCC-97H comparing MHCC-97H cells overexpressed ROCK1 with MHCC-97H cells overexpressed ROCK2 protein. Goal was to determine the distinction of ROCK1 & 2 on global MHCC-97H cell mRNA and lncRNA expression.

2019-06-19 | GSE122145 | GEO

Whole-genome gene expression profiling of UGT2B15 Knockdown/Negative Control MHCC-97H Cell Line

Project description:Whole-genome gene expression profiling of MHCC-97H cells, to further dissect the possible molecular mechanisms mediated by UGT2B15 downregulation.

2019-02-12 | GSE97387 | GEO

mRNA expression profile in MHCC-97H-SH-NC And MHCC-97H-SH-UCK2 liver cancer cells

Project description:To study the mRNA modulating network and different expressed mRNA lists in MHCC-97H-SH-UCK2 cells, we use high-throughout method to genomically detect the expression profile of mRNA

2018-11-29 | GSE123039 | GEO

mRNA expression profile in MHCC-97H-SH-NC And MHCC-97H-SH-UCK2 liver cancer cells

Project description:mRNA expression profile in MHCC-97H-SH-NC And MHCC-97H-SH-UCK2 liver cancer cells

| PRJNA507372 | ENA

Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma

Project description:Lenvatinib targets multiple oncogenic kinases including vascular endothelial growth factor receptors (VEGFRs) and showed longer median progression-free survival than sorafenib, the only approved treatment for >10 years. With the successful combination therapy of anti-PD-L1 pembrolizumab and anti-VEGF bevacizumab for advanced HCC as well as encouraging experimental findings, lenvatinib was also expected to enhance anti-tumor effects by combining anti-PD-1 pembrolizumab compared to lenvatinib alone; however, the phase III clinical trial failed to show their synergetic survival benefits, highlighting the need for elucidating its mode of action in human HCC specimens after lenvatinib treatment. We performed multi-layer transcriptome analyses of surgically resected human HCC samples after lenvatinib treatment as a neo-adjuvant therapy using RNA-sequencing. Molecular pathway analyses and immunohistochemistry revealed that VEGF-mediated aberrant vascularity and cytotoxic GZMK+CD8 T cells infiltration were significantly improved in lenvatinib-treated HCC; however, the majority of these cytotoxic T cells were trapped in the intratumor fibrotic stroma, suggesting that lenvatinib-treated HCC is in the so-called excluded condition. Excluded tumors are generally believed to be less responsive to immune checkpoint inhibitors, which might be the reason the combination therapy failed to show the additive benefits.

2023-08-08 | GSE223201 | GEO

Single cell RNA sequencing of immune cells from lenvatinib-resistant mouse HCC model after lenvatinib or combined lenvatinib and CDK4/6 inhibitor palbociclib treatment

Project description:We used single-cell RNA sequencing (scRNA seq) to elucidate the alterations of tumor microenvironment upon combined treatment of lenvatinib and palbociclib (combo).

2023-09-27 | GSE218010 | GEO

RNA Sequencing of HCC cells after lenvatinib, gefitinib, and combination treatment

Project description:Using a kinome-centred CRISPR/Cas9 genetic screen, we identify here that inhibition of the epidermal growth factor receptor (EGFR) is synthetic lethal with lenvatinib in liver cancer cells. We found that the combination of the EGFR inhibitor gefitinib and lenvatinib displays potent anti-proliferative effect in HCC cell lines that express EGFR in vitro and of xenografted HCC cell lines or patient-derived HCC tumours in mice. Herre, we analyzed the different transcriptome profiling of HCC cells treated with DMSO, lenvatinib, gefitinib, and lenvatinib plus gefitinib by RNA-sequencing.

2021-07-22 | GSE157905 | GEO

Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma

Project description:To investigate the mechanism of lenvatinib resistance, we established the lenvatinib resistant Huh7 (Huh7 LR) cells by continuous exposuring to lenvatinib (1–20 μM) for approximately 10 months. We then performed gene expression profiling analysis using data obtained from RNA-seq of Huh7 parental (Huh7 P) cells and the lenvatinib resistant Huh7 (Huh7 LR) cells.

2022-08-26 | GSE211850 | GEO

The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma

Project description:To understand the role of HIF1a in lenvatinib resistance, we conducted label-free quantitative proteome analysis in both control and lenvatinib resistance cell lines. This analysis revealed changes in the proteome due to the lenvatinib resistance, providing a valuable reference for further investigations.

2024-08-20 | PXD054805 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data